{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:28Z","timestamp":1792783408973,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Swiss Federal Office of Public Health","id":[{"id":"https:\/\/ror.org\/01qtc5416","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40258-026-01063-1","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:46:11Z","timestamp":1786549571000},"page":"1117-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0903-3604","authenticated-orcid":false,"given":"Jamie","family":"Bainbridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-1440","authenticated-orcid":false,"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6599-7425","authenticated-orcid":false,"given":"Charlotte","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Jenal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"von Dombrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-6537","authenticated-orcid":false,"given":"Amy","family":"Dymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"1063_CR1","unstructured":"P\u00e9diatrie Suisse, Kinder\u00e4rzte Schweiz, Pediatric Infectious disease Group of Switzerland, Swiss Society of Neonatology, Swiss Society of Pediatric Pneumology, Swiss Society of Pediatric Cardiology, et al. Consensus statement\/recommendation on the prevention of respiratory synctial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus). 2024."},{"issue":"3","key":"1063_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","volume":"45","author":"AT Borchers","year":"2013","unstructured":"Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus\u2014a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331\u201379. https:\/\/doi.org\/10.1007\/s12016-013-8368-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/s2213-2600(15)00255-6","volume":"3","author":"NI Mazur","year":"2015","unstructured":"Mazur NI, Martin\u00f3n-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888\u2013900. https:\/\/doi.org\/10.1016\/s2213-2600(15)00255-6.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1063_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02932-5","volume":"21","author":"B Cong","year":"2023","unstructured":"Cong B, Dighero I, Zhang T, Chung A, Nair H, Li Y. Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC Med. 2023;21(1):224. https:\/\/doi.org\/10.1186\/s12916-023-02932-5.","journal-title":"BMC Med"},{"issue":"5, Supplement","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1067\/S0022-3476(03)00509-2","volume":"143","author":"SD Horn","year":"2003","unstructured":"Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5, Supplement):133\u201341. https:\/\/doi.org\/10.1067\/S0022-3476(03)00509-2.","journal-title":"J Pediatr"},{"issue":"11","key":"1063_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s12519-023-00743-5","volume":"19","author":"MY Jiang","year":"2023","unstructured":"Jiang MY, Duan YP, Tong XL, Huang QR, Jia MM, Yang WZ, et al. Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr. 2023;19(11):1030\u201340. https:\/\/doi.org\/10.1007\/s12519-023-00743-5.","journal-title":"World J Pediatr"},{"issue":"8","key":"1063_CR7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1017\/S0950268815003015","volume":"144","author":"N Homaira","year":"2016","unstructured":"Homaira N, Oei JL, Mallitt KA, Abdel-Latif ME, Hilder L, Bajuk B, et al. High burden of RSV hospitalization in very young children: a data linkage study. Epidemiol Infect. 2016;144(8):1612\u201321. https:\/\/doi.org\/10.1017\/S0950268815003015.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"1063_CR8","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1542\/peds.113.6.1758","volume":"113","author":"MK Iwane","year":"2004","unstructured":"Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004;113(6):1758\u201364. https:\/\/doi.org\/10.1542\/peds.113.6.1758.","journal-title":"Pediatrics"},{"issue":"10","key":"1063_CR9","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/jpc.16197","volume":"58","author":"E Binns","year":"2022","unstructured":"Binns E, Tuckerman J, Licciardi PV, Wurzel D. Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions. J Paediatr Child Health. 2022;58(10):1741\u20136. https:\/\/doi.org\/10.1111\/jpc.16197.","journal-title":"J Paediatr Child Health"},{"issue":"12","key":"1063_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/thx.2009.121582","volume":"65","author":"N Sigurs","year":"2010","unstructured":"Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18\u2005years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045\u201352. https:\/\/doi.org\/10.1136\/thx.2009.121582.","journal-title":"Thorax"},{"key":"1063_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.649003","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tong L, Li M, Wang Y, Li L, Yang D, et al. Recurrent wheezing and asthma after respiratory syncytial virus bronchiolitis. Front Pediatr. 2021;9:649003. https:\/\/doi.org\/10.3389\/fped.2021.649003.","journal-title":"Front Pediatr"},{"issue":"39","key":"1063_CR12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.39.2400119","volume":"29","author":"M Stucki","year":"2003","unstructured":"Stucki M, Lenzin G, Agyeman PK, Posfay-Barbe KM, Ritz N, Tr\u00fcck J, et al. Inpatient burden of respiratory syncytial virus (RSV) in Switzerland, 2003 to 2021: an analysis of administrative data. Euro Surveill. 2003;29(39):2400119. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.39.2400119.","journal-title":"Euro Surveill"},{"issue":"2","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s15010-008-8130-z","volume":"37","author":"TM Berger","year":"2009","unstructured":"Berger TM, Aebi C, Duppenthaler A, Stocker M, The Swiss Pediatric Surveillance U. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001\u20132005). Infection. 2009;37(2):109\u201316. https:\/\/doi.org\/10.1007\/s15010-008-8130-z.","journal-title":"Infection"},{"key":"1063_CR14","unstructured":"Agyemana P, Barazzoneb C, Hammerb J, Heiningera U, Nadala D, Pfammatterc J-P, et al. Consensus statement on the prevention of respiratory syncytial virus (RSV) infections with the humanized monoclonal antibody palivizumab (Synagis\u00ae). Paediatrica. 2017;28."},{"key":"1063_CR15","unstructured":"Swissmedic. Abrysvo\u00ae, powder and solvent for solution for injection [German]. 2024. [cited 12 December 2025]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/abryso-pulver-antigenum.html."},{"key":"1063_CR16","unstructured":"Swissmedic. Arexvy\u00ae (active substance: respiratory syncytial virus (RSV) pre-fusion F protein). 2024. [cited 12 December 2025]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/about-us\/publications\/public-summary-swiss-par\/public-summary-swiss-par-arexvy.html."},{"key":"1063_CR17","unstructured":"Swissmedic. mRESVIA\u00ae (active substance: respiratory syncytial virus (RSV) mRNA vaccine (nucleoside-modified)). 2025. [cited 23 February 2026]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/about-us\/publications\/public-summary-swiss-par\/public-summary-swiss-par-mresvia.html."},{"key":"1063_CR18","unstructured":"Federal Office of Public Health. The use of RSV vaccination in pregnant women. 2025. [cited 11 December 2025]. Available from: https:\/\/www.bag.admin.ch\/en\/the-use-of-rsv-vaccination-in-pregnant-women."},{"key":"1063_CR19","unstructured":"Swissmedic. Abrysvo\u00ae, powder and solvent for solution for injection [German]. 2024. [cited 09 October 2024]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/abryso-pulver-antigenum.html."},{"key":"1063_CR20","unstructured":"Federal Statistical Office. Live births per month and fertility since 1803. Neuch\u00e2tel: Federal Statistical Office; 2023. [cited 2 October 2024]. Available from: https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/population\/births-deaths.assetdetail.32506840.html."},{"issue":"10","key":"1063_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027834","volume":"9","author":"V Skrivankova","year":"2019","unstructured":"Skrivankova V, Zwahlen M, Adams M, Low N, Kuehni C, Egger M. Spatial epidemiology of gestational age and birth weight in Switzerland: census-based linkage study. BMJ Open. 2019;9(10):e027834. https:\/\/doi.org\/10.1136\/bmjopen-2018-027834.","journal-title":"BMJ Open"},{"issue":"6","key":"1063_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40121-024-00975-6","volume":"13","author":"J Alvarez Aldean","year":"2024","unstructured":"Alvarez Aldean J, Rivero Calle I, Rodriguez Fernandez R, Aceituno Mata S, Bellmunt A, Prades M, et al. Cost-effectiveness analysis of maternal immunization with RSVpreF vaccine for the prevention of respiratory syncytial virus among infants in Spain. Infect Dis Ther. 2024;13(6):1315\u201331. https:\/\/doi.org\/10.1007\/s40121-024-00975-6.","journal-title":"Infect Dis Ther"},{"issue":"21","key":"1063_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126164","volume":"42","author":"GB Gebretekle","year":"2024","unstructured":"Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE, Killikelly A, et al. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants. Vaccine. 2024;42(21):126164. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126164.","journal-title":"Vaccine"},{"issue":"9","key":"1063_CR24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","volume":"41","author":"AM Getaneh","year":"2023","unstructured":"Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, van Summeren J, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023;41(9):1623\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058.","journal-title":"Vaccine"},{"issue":"1","key":"1063_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09642-0","volume":"24","author":"R Gil-Prieto","year":"2024","unstructured":"Gil-Prieto R, Perez JJ, Drago G, Kieffer A, Roiz J, Kazmierska P, et al. Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain. BMC Infect Dis. 2024;24(1):924. https:\/\/doi.org\/10.1186\/s12879-024-09642-0.","journal-title":"BMC Infect Dis"},{"key":"1063_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100829","volume":"38","author":"D Hodgson","year":"2024","unstructured":"Hodgson D, Wilkins N, van Leeuwen E, Watson CH, Crofts J, Flasche S, et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur. 2024;38:100829. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100829.","journal-title":"Lancet Reg Health Eur."},{"issue":"Suppl 2","key":"1063_CR27","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","volume":"226","author":"A Kieffer","year":"2022","unstructured":"Kieffer A, Beuvelet M, Sardesai A, Musci R, Milev S, Roiz J, et al. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis. 2022;226(Suppl 2):S282\u201392. https:\/\/doi.org\/10.1093\/infdis\/jiac216.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"1063_CR28","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","volume":"226","author":"X Li","year":"2022","unstructured":"Li X, Bilcke J, Fernandez LV, Bont L, Willem L, Wisloff T, et al. Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J Infect Dis. 2022;226(Suppl 1):S95\u2013101. https:\/\/doi.org\/10.1093\/infdis\/jiac064.","journal-title":"J Infect Dis"},{"key":"1063_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101141","volume":"41","author":"S Nourbakhsh","year":"2021","unstructured":"Nourbakhsh S, Shoukat A, Zhang K, Poliquin G, Halperin D, Sheffield H, et al. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: a case study of Nunavik, Canada. EClinicalMedicine. 2021;41:101141. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101141.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1063_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07745-0","volume":"22","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Carmo M, Platero L, Drago G, L\u00f3pez-Belmonte J, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759. https:\/\/doi.org\/10.1186\/s12879-022-07745-0.","journal-title":"BMC Infect Dis"},{"key":"1063_CR31","unstructured":"Nirsevimab expert working group. Consensus statement\/recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus\u00ae). Liebefeld: 2024. Available from: https:\/\/www.sggg.ch\/fileadmin\/user_upload\/EMP_240215_RSV_Nirsevimab_Consensus_statement_infants_final.pdf."},{"key":"1063_CR32","unstructured":"Federal Statistical Office (FSO). Medizinische Statistik der Krankenh\u00e4user: Standardtabellen Switzerland: Federal Statistical Office: 2019."},{"issue":"16","key":"1063_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364. https:\/\/doi.org\/10.1056\/nejmoa2216480.","journal-title":"N Engl J Med"},{"issue":"26","key":"1063_CR34","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/nejmoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425\u201335. https:\/\/doi.org\/10.1056\/nejmoa2309189.","journal-title":"N Engl J Med"},{"issue":"9","key":"1063_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/nejmoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346. https:\/\/doi.org\/10.1056\/nejmoa2110275.","journal-title":"N Engl J Med"},{"issue":"25","key":"1063_CR36","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.vaccine.2022.04.076","volume":"40","author":"ML Areta","year":"2022","unstructured":"Areta ML, Valiton A, Diana A, Morales M, Wiederrecht-Gasser J, Jacob S, et al. Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: a multicentric, prospective, survey-based study. Vaccine. 2022;40(25):3455\u201360. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.076.","journal-title":"Vaccine"},{"key":"1063_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100629","volume":"28","author":"A Shoukat","year":"2023","unstructured":"Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study. Lancet Reg Health Am. 2023;28:100629. https:\/\/doi.org\/10.1016\/j.lana.2023.100629.","journal-title":"Lancet Reg Health Am."},{"issue":"40","key":"1063_CR38","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1016\/j.vaccine.2013.07.024","volume":"31","author":"SA Regnier","year":"2013","unstructured":"Regnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine. 2013;31(40):4347\u201354. https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.024.","journal-title":"Vaccine"},{"key":"1063_CR39","unstructured":"Federal Statistical Office. Infant mortality and stillbirths. Neuch\u00e2tel: Federal Statistical Office; 2024. [cited 18 September 2024]. Available from: https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/health\/state-health\/mortality-causes-death\/infant-stillbirths.html."},{"issue":"12","key":"1063_CR40","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.299.12.1429","volume":"299","author":"GK Swamy","year":"2008","unstructured":"Swamy GK, Skj\u0160rven R. Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth. JAMA. 2008;299(12):1429\u201336. https:\/\/doi.org\/10.1001\/jama.299.12.1429.","journal-title":"JAMA"},{"issue":"1","key":"1063_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08358-x","volume":"23","author":"F Martin\u00f3n-Torres","year":"2015","unstructured":"Martin\u00f3n-Torres F, Carmo M, Platero L, Drago G, L\u00f3pez-Belmonte J, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015\u20132018. BMC Infect Dis. 2015;23(1):385. https:\/\/doi.org\/10.1186\/s12879-023-08358-x.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1063_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpeds.2010.02.006","volume":"157","author":"CF Gunville","year":"2010","unstructured":"Gunville CF, Sontag MK, Stratton KA, Ranade DJ, Abman SH, Mourani PM. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr. 2010;157(2):209-14.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2010.02.006.","journal-title":"J Pediatr"},{"key":"1063_CR43","unstructured":"German Society for Infectious Diseases. RSV vaccination in particularly vulnerable patients. Berlin: German Society for Infectious Diseases; 2024. [cited 10 December 2024]. Available from: https:\/\/www.dgi-net.de\/rsv-schutzimpfung-bei-besonders-gefaehrdeten-patientinnen-und-patienten\/."},{"key":"1063_CR44","unstructured":"Swiss National Bank. Foreign exchange rates \u2013 Year. Z\u00fcrich: Swiss National Bank; 2024. [cited 12 December 2025]. Available from: https:\/\/data.snb.ch\/en\/topics\/ziredev\/cube\/devkua?fromDate=2013&dimSel=D1(EUR1)."},{"key":"1063_CR45","unstructured":"Swiss Federal Office of Public Health. Preparations specialty list. Liebefeld: Swiss Federal Office of Public Health; 2024. [cited 18 September 2024]. Available from: https:\/\/www.xn--spezialittenliste-yqb.ch\/ShowPreparations.aspx."},{"key":"1063_CR46","unstructured":"Federal Office of Public Health. EDI regulation about benefits in compulsory health insurance [German]. 2025. [cited 23 February 2026]. Available from: https:\/\/www.fedlex.admin.ch\/eli\/oc\/2025\/419\/de."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01063-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:22:39Z","timestamp":1792585359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01063-1","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"York Health Economics Consortium was commissioned by the Swiss Federal Office of Public Health to conduct this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data supporting the findings of this study are available in the full HTA report published by the FOPH:","order":2,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication (from patients\/participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation: All authors. Methodology: JB, SM, AD, MJ and NV. Formal analysis and investigation: All authors. Writing \u2013 original draft preparation: AD, SJM and CG. Writing \u2013 review and editing: All authors. Funding acquisition: MJ, NV. Supervision: SJM, AD.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}